March 2026 Research Update

Brain imaging studies this month add a clearer picture that Friedreich ataxia affects both brain structure (volume loss) and brain network communication, and that these changes can relate to symptoms. Across studies, some imaging signals tracked with disease severity or symptom duration, and one pediatric study pointed to early support-cell activation rather than clear nerve-cell loss in the regions measured. Taken together, these results strengthen the idea that imaging can capture more than one pathway of change in FRDA, which may matter for understanding differences between people and over time. [1] [2] [3]

In people with FRDA, one study reported widespread shrinking in parts of the brain involved in movement and coordination, especially the brainstem, cerebellar white matter, and thalamus. It also reported that some brain connections were weaker (front-to-cerebellum) while other connections were stronger (within the cerebellum and between certain deep brain regions), and several of these measures related to clinical severity and to motor and cognitive performance. A practical takeaway is that FRDA-related changes are not limited to one spot, and different kinds of brain-network changes may show up at different points in the disease. [1]

A larger multicenter analysis used structural MRI patterns to group people with FRDA into three imaging-based subtypes (called classical, early cerebral, and early cerebellar) and to estimate an imaging-based stage. Higher stage was linked to longer symptom duration and greater clinical severity, although the link between stage and clinical measures was weaker in the early cerebral subtype. This adds to the idea that FRDA may not look the same in the brain for everyone, even when people share the same diagnosis. [2]

In children with FRDA, a spectroscopy study (a type of MRI that measures brain chemicals) found higher myo-inositol, with no clear differences in two other measured chemicals (GSH and GABA+). The ratio of tNAA to myo-inositol was lower mainly because myo-inositol was higher, while tNAA itself did not differ. The authors interpreted this pattern as more consistent with early reactive gliosis (increased activity of support cells) than with clear neuron loss in the measured regions. [3]

For patients and caregivers, these imaging studies mainly add understanding rather than changing care right now. They suggest that MRI can capture several parts of FRDA at once, including brain shrinking, altered communication between brain regions, and possible early support-cell changes in children, and that some of these measures line up with symptom severity or duration. What remains uncertain is how well any single imaging measure predicts an individual person's future, and which measures are most useful for tracking change over time. This body of work may matter most for research studies that need ways to describe disease stage or to separate different patterns of FRDA in the future. [1] [2] [3]

This month, studies looking at genes and cell signals did not report a single new clinical biomarker ready for use, but they did sharpen what kinds of molecular changes tend to repeat across FRDA datasets. One paper combined many human RNA studies and highlighted a small set of genes that were repeatedly higher in disease-relevant cells, suggesting a more consistent molecular fingerprint than any one study can provide. Another paper mapped where GAA repeats and other repeat types occur across the genome in healthy people, helping place the FRDA repeat expansion in the broader landscape of human DNA repeats. [4] [5]

Across multiple human bulk RNA datasets, a meta-analysis reported recurring changes beyond low frataxin (FXN), including signals related to long non-coding RNAs, protein production control, and cell structure organization. It highlighted MYH14, MEG9, and MEG8 as candidate biomarkers because they were repeatedly higher and especially prominent in sensory neurons and heart muscle cells, which are relevant to FRDA symptoms. The study also reported that these transcription changes were pharmacologically modifiable in the included models and datasets, and it released an interactive FRDA Transcriptomic Atlas to help explore patterns across studies. [4]

A genome-wide analysis in 191 healthy individuals compared three repeat motifs (CGG, CAG, and GAA) and reported that GAA repeats were the most abundant and showed the highest overall variability. It also reported that different repeat motifs tended to cluster in different parts of the genome, and that disease-linked repeat sites tended to be larger than typical repeats. While this study did not focus on people with FRDA, it helps explain why some repeat types may be more prone to instability and why their location in DNA may matter. [5]

For patients, these results are mainly research that builds a more detailed map of what is changing inside cells in FRDA and how repeat DNA sequences behave in the genome. The RNA meta-analysis helps clarify which gene signals show up again and again across studies, which is a step toward lab tests that might someday help track disease activity or treatment response, but it does not establish a test used in routine care. The repeat biology work helps clarify the wider context of the FRDA-related GAA repeat, but it does not by itself change diagnosis or monitoring. What remains uncertain is which of these molecular signals will prove reliable in real-world patient samples over time, and which will be most meaningful for symptoms. [4] [5]

This month included one detailed individual clinical report and one laboratory resource report, both of which are early pieces of evidence rather than broad answers for most families. The clinical case shows that advanced heart care, including heart transplantation, can be part of the real-world FRDA story for some people, with longer follow-up described. The lab report adds a new patient-derived cell model aimed at studying a specific FXN splicing mutation, which can support future therapy development but does not itself test a treatment. [6] [7]

In a single 39-year-old man with late-onset FRDA and advanced heart failure, a heart transplant was reported after temporary mechanical heart support, and he was described as living at home and remaining ambulatory with no readmissions at 2.5 years of follow-up. The report also noted that omaveloxolone was started 1 year after transplantation, without providing broader outcome comparisons. This case mainly illustrates what was possible for one person and highlights the long-term medical complexity that can occur in FRDA. [6]

A separate laboratory report described creating induced pluripotent stem cells (iPSCs) from blood cells of one FRDA patient with an FXN splice-site change (c.165+5G>C). The key result is the successful creation of a patient-derived cell line that carries this mutation, which can be used to study the splicing problem and to test ideas that target splicing in the lab. This is groundwork research and does not provide evidence about patient outcomes. [7]

For patients and caregivers, the case report may matter now mainly as a documented example of a complex heart-care pathway in FRDA, but it cannot tell how often similar outcomes occur or who might be eligible. The iPSC model may matter later by enabling more targeted lab testing for a specific genetic subgroup, but it is not a treatment study. What remains uncertain is how well either report generalizes to other people with FRDA, since both are based on a single individual. [6] [7]